Can Opicapone be purchased in China? When was it launched?

Opicapone (Opicapone) is a drug used to treat Parkinson's disease. It is mainly used to help control the motor complications that occur in patients with Parkinson's disease during long-term treatment with levodopa. Opicapone is a catechol-O-methyltransferase inhibitor (COMT). By prolonging the action time of levodopa in the body, it can improve the effect of levodopa and reduce the symptoms of movement disorders in patients with Parkinson's disease. The launch of Opicapone is of great significance to patients with Parkinson's disease and can improve their quality of life.

Opicapone has not yet been approved for marketing in China, so it cannot be purchased in domestic pharmacies or hospitals. If patients need to use Opicapone to treat Parkinson's disease, it is recommended to consult a professional doctor or medical institution to seek other alternative drugs or treatment options.

Opicapone is available as 25mg and 50mghard capsules, with the recommended dose of 50mg taken at bedtime at least one hour after carbidopa/levodopa. No dose adjustment is required in elderly patients, patients with renal impairment, and patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment, so the use of opicapone is not recommended in this population.

The availability of Opicapone varies by country and region. Opicapone has been approved for marketing in Europe and the United States and is gradually entering the market. However, in China, the launch time of Opicapone depends on the drug registration and approval procedures and schedule. Patients can learn about the latest listing of Opicapone in China by paying attention to the drug approval announcements of the State Food and Drug Administration or consulting relevant pharmaceutical companies.